vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and Perella Weinberg Partners (PWP). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $219.2M, roughly 1.5× Perella Weinberg Partners). HAEMONETICS CORP runs the higher net margin — 13.2% vs 6.3%, a 6.9% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -2.9%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $30.5M). Over the past eight quarters, Perella Weinberg Partners's revenue compounded faster (46.5% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
PJT Partners, Inc. is a global advisory-focused investment bank, founded in October 2015 as part of The Blackstone Group's spin-off of its financial and strategic advisory services businesses.
HAE vs PWP — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $219.2M |
| Net Profit | $44.7M | $13.8M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 8.5% |
| Net Margin | 13.2% | 6.3% |
| Revenue YoY | -2.7% | -2.9% |
| Net Profit YoY | 19.3% | — |
| EPS (diluted) | $0.95 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $219.2M | ||
| Q3 25 | $327.3M | $164.6M | ||
| Q2 25 | $321.4M | $155.3M | ||
| Q1 25 | $330.6M | $211.8M | ||
| Q4 24 | $348.5M | $225.7M | ||
| Q3 24 | $345.5M | $278.2M | ||
| Q2 24 | $336.2M | $272.0M | ||
| Q1 24 | — | $102.1M |
| Q4 25 | $44.7M | $13.8M | ||
| Q3 25 | $38.7M | $6.0M | ||
| Q2 25 | $34.0M | $2.7M | ||
| Q1 25 | $58.0M | $17.3M | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $33.8M | $16.4M | ||
| Q2 24 | $38.4M | $-66.0M | ||
| Q1 24 | — | $-35.8M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 8.5% | ||
| Q3 25 | 17.9% | 5.4% | ||
| Q2 25 | 16.8% | 5.8% | ||
| Q1 25 | 21.6% | 5.5% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 15.0% | 12.9% | ||
| Q2 24 | 11.8% | -30.2% | ||
| Q1 24 | — | -52.4% |
| Q4 25 | 13.2% | 6.3% | ||
| Q3 25 | 11.8% | 3.6% | ||
| Q2 25 | 10.6% | 1.8% | ||
| Q1 25 | 17.5% | 8.2% | ||
| Q4 24 | 10.8% | — | ||
| Q3 24 | 9.8% | 5.9% | ||
| Q2 24 | 11.4% | -24.3% | ||
| Q1 24 | — | -35.1% |
| Q4 25 | $0.95 | $0.11 | ||
| Q3 25 | $0.81 | $0.08 | ||
| Q2 25 | $0.70 | $0.04 | ||
| Q1 25 | $1.17 | $0.24 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.66 | $0.24 | ||
| Q2 24 | $0.74 | $-1.21 | ||
| Q1 24 | — | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $255.9M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $-127.4M |
| Total Assets | $2.5B | $797.6M |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $255.9M | ||
| Q3 25 | $296.4M | $185.5M | ||
| Q2 25 | $292.9M | $145.0M | ||
| Q1 25 | $306.8M | $111.2M | ||
| Q4 24 | $320.8M | $407.4M | ||
| Q3 24 | $299.3M | $335.1M | ||
| Q2 24 | $344.4M | $185.3M | ||
| Q1 24 | — | $156.7M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $-127.4M | ||
| Q3 25 | $849.2M | $-302.4M | ||
| Q2 25 | $882.3M | $-318.4M | ||
| Q1 25 | $820.8M | $-323.1M | ||
| Q4 24 | $906.9M | $-421.4M | ||
| Q3 24 | $878.9M | $-360.8M | ||
| Q2 24 | $905.4M | $-283.0M | ||
| Q1 24 | — | $161.9M |
| Q4 25 | $2.5B | $797.6M | ||
| Q3 25 | $2.4B | $650.2M | ||
| Q2 25 | $2.5B | $606.7M | ||
| Q1 25 | $2.5B | $570.5M | ||
| Q4 24 | $2.5B | $876.8M | ||
| Q3 24 | $2.5B | $810.9M | ||
| Q2 24 | $2.5B | $645.5M | ||
| Q1 24 | — | $583.6M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $34.8M |
| Free Cash FlowOCF − Capex | $87.2M | $30.5M |
| FCF MarginFCF / Revenue | 25.7% | 13.9% |
| Capex IntensityCapex / Revenue | 1.9% | 2.0% |
| Cash ConversionOCF / Net Profit | 2.09× | 2.52× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-34.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $34.8M | ||
| Q3 25 | $111.3M | $59.2M | ||
| Q2 25 | $17.4M | $56.1M | ||
| Q1 25 | $116.6M | $-176.5M | ||
| Q4 24 | $43.8M | $223.4M | ||
| Q3 24 | $48.8M | $200.3M | ||
| Q2 24 | $-27.4M | $90.0M | ||
| Q1 24 | — | $-206.3M |
| Q4 25 | $87.2M | $30.5M | ||
| Q3 25 | $106.3M | $57.6M | ||
| Q2 25 | $13.6M | $55.3M | ||
| Q1 25 | $100.9M | $-177.6M | ||
| Q4 24 | $35.2M | $207.0M | ||
| Q3 24 | $39.4M | $199.3M | ||
| Q2 24 | $-33.1M | $83.7M | ||
| Q1 24 | — | $-214.8M |
| Q4 25 | 25.7% | 13.9% | ||
| Q3 25 | 32.5% | 35.0% | ||
| Q2 25 | 4.2% | 35.6% | ||
| Q1 25 | 30.5% | -83.8% | ||
| Q4 24 | 10.1% | 91.7% | ||
| Q3 24 | 11.4% | 71.6% | ||
| Q2 24 | -9.8% | 30.8% | ||
| Q1 24 | — | -210.3% |
| Q4 25 | 1.9% | 2.0% | ||
| Q3 25 | 1.5% | 0.9% | ||
| Q2 25 | 1.2% | 0.5% | ||
| Q1 25 | 4.7% | 0.5% | ||
| Q4 24 | 2.5% | 7.3% | ||
| Q3 24 | 2.7% | 0.4% | ||
| Q2 24 | 1.7% | 2.3% | ||
| Q1 24 | — | 8.3% |
| Q4 25 | 2.09× | 2.52× | ||
| Q3 25 | 2.88× | 9.85× | ||
| Q2 25 | 0.51× | 20.50× | ||
| Q1 25 | 2.01× | -10.18× | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | 12.23× | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
PWP
Segment breakdown not available.
